Moreover, CXCR4’s involvement in drug resistance, particularly in trastuzumab treatment, has been well documented, reinforcing its critical role in the therapeutic landscape of HER2 breast cancer [45,46]. This evidence concerns the gene ERBB2 and breast carcinoma.